Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of tanespimycin plus bortezomib versus bortezomib alone in first-relapse multiple myeloma
2007-004138-17Phase 3Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2007
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Tanespimycin + Velcade with Velcade alone (2 arms). Primary endpoint: Progression-free survival. Started Dec 2007; status: terminated.
02
Drugs
tanespimycinbortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2007-004138-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004138-17.